RecruitingCirrhosis, Liver
EGCG for Hepatocellular Carcinoma Chemoprevention
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This phase II trial tests epigallocatechin gallate (EGCG) for its efficacy and safety in preventing development of hepatocellular carcinoma (HCC) in patients with liver cirrhosis.
Sponsor: University of Texas Southwestern Medical Center
You may qualify if…
- ✓ Adults (≥ 18 years-old)
- ✓ Clinically and/or histologically diagnosed cirrhosis
- ✓ No active hepatic decompensation
- ✓ No prior history of HCC
- ✓ Adequate hematologic, hepatic, and renal function
- ✓ Karnofsky performance status score ≥70
- ✓ Both sexes and all racial/ethnic groups will be considered
- ✓ FIB-4 index \> 3.25
You may not qualify if…
- ✕ Prior or ongoing use of EGCG
- ✕ History of adverse reaction to green tea products
- ✕ Severe obesity (BMI \> 40 kg/m2)
- ✕ Active drinking
- ✕ EGCG treatment \<4 weeks or \<80% of planned regimen at the end of week 4
- ✕ HCC development during the study
Where it's recruiting
Texas
Dallas
Source: ClinicalTrials.gov · NCT06015022 · last updated 2025-09-05